RPRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Royalty Pharma plc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$60.27−0.69 (-1.13%)
Close on Oct 19, 2026
- Market cap
- $33.56B
- P/E (TTM)
- 34.2
- Dividend yield
- –
Royalty Pharma plc revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income from financial royalty assets | $638.03M | $594.99M | $592.43M | $578.81M | $550.42M | $539.49M | $561.85M | $533.17M | $512.87M | $541.55M | $523.07M | $508.66M | 94.6% | +15.9% |
| Other royalty income and revenues | $36.11M | $35.58M | $29.56M | $30.48M | $28.25M | $28.76M | $31.80M | $31.52M | $24.40M | $26.43M | $73.00M | $27.66M | 5.4% | +27.9% |
| Revenue from intangible royalty assets | – | – | – | – | – | – | – | – | – | – | $238.00K | $252.00K | – | – |
By region
From the segment and revenue-disaggregation notes of Royalty Pharma's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.